Prognostic Utility of Neutrophil Gelatinase-Associated Lipocalin in Predicting Mortality and Cardiovascular Events in Patients With ST-Segment Elevation Myocardial Infarction Treated With Primary Percutaneous Coronary Intervention

Lindberg, Søren; Pedersen, Sune; Møgelvang, Rasmus; Jensen, Jan Skov; Flyvbjerg, Allan; Galatius, Søren; Magnusson, Nils E.

doi:10.1016/j.jacc.2012.04.017

Cited by 94 publications

(79 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

Section: Inflammationmentioning

confidence: 99%

“…133 Increased levels of neutrophil gelatinaseassociated lipocalin are associated with an increased risk of all-cause mortality and adverse cardiovascular events in patients with ST-segment-elevation MI. 133 Neutrophil gelatinaseassociated lipocalin forms a complex with MMP9 and prevents its degradation. 108 Levels of this complex may be predictive of adverse cardiovascular events in patients with ACS undergoing coronary angiography.…”

Section: Inflammationmentioning

confidence: 99%

“…Neutrophil gelatinaseassociated lipocalin is stored in neutrophil granules and is released by damaged tubular cells and may also have a role in atherosclerosis. 133 Increased levels of neutrophil gelatinaseassociated lipocalin are associated with an increased risk of all-cause mortality and adverse cardiovascular events in patients with ST-segment-elevation MI.133 Neutrophil gelatinaseassociated lipocalin forms a complex with MMP9 and prevents its degradation.108 Levels of this complex may be predictive of adverse cardiovascular events in patients with ACS undergoing coronary angiography. 109 Neutrophils release neutrophil extracellular traps, which consist of extruded DNA, during ACS, and neutrophil extracellular traps contribute toward the meshwork of a thrombus.…”

mentioning

confidence: 99%

See 2 more Smart Citations

Novel Risk Markers and Risk Assessments for Cardiovascular Disease

Thomas

Lip

2017

Circulation Research

115

View full text Add to dashboard Cite

Abstract:The use of risk markers has transformed cardiovascular medicine, exemplified by the routine assessment of troponin, for both diagnosis and assessment of prognosis in patients with chest pain. Clinical risk factors form the basis for risk assessment of cardiovascular disease and the addition of biochemical, cellular, and imaging parameters offers further refinement. Identifying novel risk factors may allow greater risk stratification and a steady, but gradual progression toward precision medicine. Indeed, the generation of data in this area of research is explosive and when combined with new technologies and techniques provides the potential for more refined, targeted approaches to cardiovascular medicine. Although discussing the most recent developments in this field, this review article aims to strike a balance between novelty and validity by focusing on recent large samplesize studies that have been validated in a separate cohort in most cases. Risk markers related to atherosclerosis, thrombosis, inflammation, cardiac injury, and fibrosis are introduced in the context of their pathophysiology. Rapidly developing new areas, such as assessment of micro-RNA, are also explored. Subsequently the prognostic ability of these risk markers in coronary artery disease, heart failure, and atrial fibrillation is discussed in detail. ( addition to these roles in the pathogenesis of coronary artery disease, lipid-related molecules have been identified to be markers of inflammation and oxidative stress (Table 1). Thrombosis-Related Risk MarkersAfter atherosclerotic plaque rupture, platelets adhere to exposed subendothelial components, such as collagen and von Willebrand factor, which promotes platelet activation and aggregation. 10 In addition, platelet activation is potentiated by exposure to released soluble agonists, such as thrombin and ADP.10 Activated platelets then further release ADP, which acts on platelet P2Y 12 ADP receptors and has a central role in amplifying the response of platelets to the initial stimulus. 10 Platelet reactivity to various agonists, including ADP, has been studied extensively in the context of acute coronary syndrome (ACS; Table 2). 11 The VerifyNow and Multiplate pointof-care tests allow for the measurement of platelet aggregation in response to stimulation, and it has been shown that high platelet reactivity is associated with adverse cardiovascular events. 26 Platelet microparticles are released on platelet activation, and their role in cardiovascular disease is an area of active investigation (Table 2). 15 Circulating microparticles are released from cells undergoing activation or apoptosis and are a type of small plasma membrane vesicle that retain defined properties from their original cell lineage. 15 Platelet activation and aggregation lead to the activation of the coagulation cascade and the formation of a stable crosslinked fibrin clot. The balance between prothrombotic factors and endogenous fibrinolysis determines whether the thrombus propagates or instead proceeds to dis...

show abstract

Section: Inflammationmentioning

confidence: 99%

Section: Inflammationmentioning

confidence: 99%

mentioning

confidence: 99%

See 1 more Smart Citation

Novel Risk Markers and Risk Assessments for Cardiovascular Disease

Thomas

Lip

2017

Circulation Research

115

View full text Add to dashboard Cite

show abstract

“…There are several studies which use NGAL for risk stratification in patients with unstable angina (UA) [9] and acute myocardial infarction (AMI) [10,11], but its role in patients with stable angina was not established. Furthermore, most of the studies concentrate on short-term outcomes.…”

Section: Discussionmentioning

confidence: 99%

Does Neutrophil Gelatinase-Asociated Lipocalin Have Prognostic Value in Patients with Stable Angina Undergoing Elective PCI? A 3-Year Follow-Up Study

Bachórzewska−Gajewska

Tomaszuk‐Kazberuk

Jarocka

et al. 2013

Kidney Blood Press Res

View full text Add to dashboard Cite

Background: Neutrophil gelatinase-associated lipocalin (NGAL), a widely accepted diagnostic marker of acute renal injury (AKI) may be involved in the development of atherosclerosis. Purpose: To assess the prognostic significance of serum and urinary NGAL and serum cystatin C in patients with stable angina undergoing percutaneous coronary intervention (PCI) on a 3-year follow-up. Methods: We included patients with stable angina undergoing PCI. Serum NGAL and cystatin C were evaluated before and 4h, 8h after PCI. Urinary NGAL was evaluated before and 12h and 24h after the procedure. The primary end-point was all-cause mortality on a 3-year follow-up. Results: Among 132 patients there were 63% of males (mean age 64,5±9,8 years). Mean eGFR was 86.2±28.5 ml/min. During follow-up 8% of the patients died. All-cause mortality was significantly higher in patients with increased urinary NGAL concentration 12h after PCI (p=0.04). Urinary NGAL 12h after PCI correlated with eGFR (p<0.05), with serum NGAL evaluated before and 4h and 8h after PCI (p<0.05) and with increased serum cystatin C evaluated 4 hours after PCI (p<0.05). Conclusions: Increased urinary NGAL concentration is a strong predictor of mortality in patients with stable angina who undergo PCI and may be used for the risk stratification in this population.

show abstract

“…135 Although a significant correlation with renal function is observed, there were elevated levels found in patients with normal GFR, suggesting a separate inflammatory pathway, and experimental models suggest within-myocardium expression of NGAL. 135 Prognostically, increased levels of NGAL were initially shown to predict mortality and cardiovascular events in STelevation MI (STEMI) patients treated with percutaneous coronary intervention (PCI), 137 but have subsequently shown to predict not only HF after STEMI 138 but also increased mortality and HF readmissions from ADHF when measured at admission. 139,140 In the GALLANT study, plasma NGAL at discharge was also predictive of 30-day outcomes, including mortality and readmissions, more so than BNP alone, but greatest in combination with BNP.…”

Section: Neutrophil Gelatinase-associated Lipocalinmentioning

confidence: 99%

Biomarkers in Acute Decompensated Heart Failure

Rosenbaum

Miller

2015

Clinical Medicine Insights: Therapeutics

View full text Add to dashboard Cite

Acute decompensated heart failure (ADHF) is a prominent condition whose frequency is increasing, especially in the context of an aging population. The ability to discern the cause of undifferentiated dyspnea in acute presentations is an increasing struggle. In this review, we seek to explore the various biomarkers that have been studied for the diagnosis of ADHF and their respective clinical utilities as the most recent data would suggest. Natriuretic peptides, galectin-3, soluble ST2, adrenomedullin, cardiac troponin-T, neutrophil gelatinase-associated lipocalin, and copeptin are reviewed. Of these biomarkers, natriuretic peptides are the most thoroughly evaluated and show the most promise for diagnosis or exclusion of acute heart failure, though other biomarkers can add significant utility in the form of prognostication.KEYWOrDs: acute decompensated heart failure, NT-proBNP, diagnosis, biomarkers CitAtion: rosenbaum and Miller. Biomarkers in acute decompensated heart Failure.

show abstract

Prognostic Utility of Neutrophil Gelatinase-Associated Lipocalin in Predicting Mortality and Cardiovascular Events in Patients With ST-Segment Elevation Myocardial Infarction Treated With Primary Percutaneous Coronary Intervention

Cited by 94 publications

References 31 publications

Novel Risk Markers and Risk Assessments for Cardiovascular Disease

Novel Risk Markers and Risk Assessments for Cardiovascular Disease

Does Neutrophil Gelatinase-Asociated Lipocalin Have Prognostic Value in Patients with Stable Angina Undergoing Elective PCI? A 3-Year Follow-Up Study

Biomarkers in Acute Decompensated Heart Failure

Contact Info

Product

Resources

About